Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Psychemedics Corporation PMD NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
23/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Psychemedics Corporation (PMD) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $2.67. It has a SharesGrow Score of 21/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $20M, -7.3%/yr average growth. Net income is $2M (loss), growing at -97%/yr. Net profit margin is -9.5% (negative). Gross margin is 36.1% (-5.1 pp trend).

Balance sheet: total debt is $1M against $5M equity (Debt-to-Equity (D/E) ratio 0.23, conservative). Current ratio is 1.82 (strong liquidity). Debt-to-assets is 14%. Total assets: $8M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 21/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

PMD SharesGrow Score Overview

28/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PMD

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
PMD: -7.3%/yr revenue is, -97%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet PMD: Debt-to-Equity (D/E) ratio 0.23 (conservative), Current ratio is 1.82 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
PMD: Gross margin is 36.1% (-5.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
PMD: Net profit margin is -9.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.6-2.67
Volume112.27K
Avg Volume (30D)31.05K
Market Cap$15.56M
Beta (1Y)0.67
Dividend Yield$0.2800
Share Statistics
EPS (TTM)-0.32
Shares Outstanding$5.87M
IPO Date1987-01-22
Employees116
CEOBrian Hullinger
Financial Highlights & Ratios
Revenue (TTM)$19.69M
Gross Profit$7.1M
EBITDA$191K
Net Income$-1.86M
Operating Income$-1.89M
Total Cash$1.42M
Total Debt$1.17M
Net Debt$-251K
Total Assets$8.32M
Price / Earnings (P/E)-8.3
Price / Sales (P/S)0.79
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS7443752057

Price Chart

Track all markets on TradingView
PMD
Psychemedics Corporation ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Diagnostics & Research
2.60 52WK RANGE 2.67

People Also View

SHC
SHC
Sotera Health Company
$15.93
+1.46%
 OLK
OLK
Olink Holding AB (publ)
$26.08
+0.31%
 CSTL
CSTL
Castle Biosciences, Inc.
$24.37
+3.57%
 GTH
GTH
Genetron Holdings Limited
$4.03
+0.12%
 FONR
FONR
FONAR Corporation
$18.76
+0.27%
 STIM
STIM
Neuronetics, Inc.
$1.43
+2.88%
 SERA
SERA
Sera Prognostics, Inc.
$2.14
+0.47%
 XGN
XGN
Exagen Inc.
$3.04
+2.36%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message